Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares shot up 28.6% during trading on Tuesday . The stock traded as high as $5.39 and last traded at $4.72, with a volume of 556,505 shares. The stock had previously closed at $3.67.

Several brokerages have recently commented on GLMD. FBR & Co set a $20.00 target price on Galmed Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 5th. Roth Capital reiterated a “buy” rating and set a $6.00 target price on shares of Galmed Pharmaceuticals in a research note on Wednesday, July 6th. Maxim Group reiterated a “buy” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, June 2nd. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research note on Monday, July 18th. Finally, HC Wainwright reiterated a “buy” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.35.

The stock’s 50 day moving average is $3.96 and its 200-day moving average is $4.68. The stock’s market capitalization is $51.51 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.04. Analysts predict that Galmed Pharmaceuticals Ltd. will post ($1.51) earnings per share for the current fiscal year.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

5 Day Chart for NASDAQ:GLMD

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.